BGI SENTIS™ Targeted Drug Therapy Panel
BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported.
BGI’s Targeted Drug Therapy Panel examines all exons and selected introns of 206 genes with direct therapeutic implications for 95 targeted therapies from a variety of sample input including fresh tissue, biopsy, FFPE, DNA and peripheral blood.
Why Choose the BGI SENTIS™ Targeted Drug Therapy Panel?
Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.
Ordering the BGI SENTIS™ Targeted Drug Therapy Panel is easy.